Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Trials
Published in: Trials 1/2018

Open Access 01-12-2018 | Study protocol

Effects of pre-transplant azithromycin administration on kidney graft function: study protocol for a double-blind randomized clinical trial

Authors: Gholamreza Mokhtari, Mojtaba Teimoori

Published in: Trials | Issue 1/2018

Login to get access

Abstract

Background

Kidney transplantation is the best strategy for the management of end-stage renal disease; however, the outcomes need to improve further. Macrolides show antimicrobial and anti-inflammatory properties in chronic diseases and intraoperatively, and can accumulate in tissues for extended periods. Therefore, theoretically, when administered to a donor and because of accumulation in the donor kidney, macrolides can cause graft immunomodulation and improve kidney transplantation outcomes.

Methods

This study is a single-center, randomized clinical trial. A total of 60 kidney donors will be randomly allocated to the azithromycin or placebo group and treated with a single dose (1 g) of azithromycin or placebo, respectively, 1 day before surgery. Recruitment commenced in September 2016 and is expected to be completed by March 2018. The primary outcome is kidney graft function. The secondary outcomes include rejection rate, urinary tract infections in graft recipients, pain and systemic inflammatory response syndrome in live donors, and complications in both donors and recipients. Outcomes will be evaluated at baseline and every day in the first week after transplantation, as well as at 1 and 3 months post transplantation. Adverse reactions will be documented. If the efficacy of azithromycin in reducing adverse outcomes is confirmed, it would serve as an easy to use, economic intervention able to lower post-transplantation risks.

Discussion

Short and mid-term analyses of blood and urine samples as well as immunological assays will facilitate a more in-depth analysis of the effects of azithromycin on transplantation outcomes.

Trial registration

Iranian Clinical Trial Registry, IRCT201606141853​N11, registered on September 5, 2016.
Appendix
Available only for authorised users
Literature
1.
Wang V, Vilme H, Maciejewski ML, Boulware LE. The economic burden of chronic kidney disease and end-stage renal disease. Semin Nephrol. 2016;36:319–30.CrossRefPubMed
2.
Wetmore JB, Collins AJ. Global challenges posed by the growth of end-stage renal disease. Ren Replace Ther. 2016;2:15.CrossRef
3.
Matas AJ, Smith JM, Skeans MA, Thompson B, Gustafson SK, Stewart DE, et al. OPTN/SRTR 2013 annual data report: kidney. Am J Transplant. 2015;15(Suppl 2):1–34.CrossRefPubMed
4.
Kirst HA. New macrolides: expanded horizons for an old class of antibiotics. J Antimicrob Chemother. 1991;28:787–90.CrossRefPubMed
5.
6.
Villa ML, Valenti F, Scaglione F, Falchi M, Fraschini F. In-vivo and in-vitro interference of antibiotics with antigen-specific antibody responses: effect of josamycin. J Antimicrob Chemother. 1989;24:765–74.CrossRefPubMed
7.
Wildfeuer A, Laufen H, Zimmermann T. Uptake of azithromycin by various cells and its intracellular activity under in vivo conditions. Antimicrob Agents Chemother. 1996;40:75–9.PubMedPubMedCentralCrossRef
8.
Solidoro P, Braido F, Boffini M, Corsico AG. New life for macrolides. Minerva Med. 2013;104:7–14.PubMed
9.
Foulds G, Shepard RM, Johnson RB. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother. 1990;25(Suppl A):73–82.CrossRefPubMed
10.
Stallone G, Infante B, Di Lorenzo A, Rascio F, Zaza G, Grandaliano G. mTOR inhibitors effects on regulatory T cells and on dendritic cells. J Transl Med. 2016;14:152.CrossRefPubMedPubMedCentral
11.
Ratzinger F, Haslacher H, Poeppl W, Hoermann G, Kovarik JJ, Jutz S, et al. Azithromycin suppresses CD4(+) T-cell activation by direct modulation of mTOR activity. Sci Rep. 2014;4:7438.CrossRefPubMedPubMedCentral
12.
Cory TJ, Birket SE, Murphy BS, Hayes D Jr, Anstead MI, Kanga JF, et al. Impact of azithromycin treatment on macrophage gene expression in subjects with cystic fibrosis. J Cyst Fibros. 2014;13:164–71.CrossRefPubMed
13.
Scaglione F, Rossoni G. Comparative anti-inflammatory effects of roxithromycin, azithromycin and clarithromycin. J Antimicrob Chemother. 1998;41(Suppl B):47–50.CrossRefPubMed
14.
Sugiyama K, Shirai R, Mukae H, Ishimoto H, Nagata T, Sakamoto N, et al. Differing effects of clarithromycin and azithromycin on cytokine production by murine dendritic cells. Clin Exp Immunol. 2007;147:540–6.CrossRefPubMedPubMedCentral
15.
Strieter RM, Kasahara K, Allen RM, Standiford TJ, Rolfe MW, Becker FS, et al. Cytokine-induced neutrophil-derived interleukin-8. Am J Pathol. 1992;141:397–407.PubMedPubMedCentral
16.
Shinkai M, Foster GH, Rubin BK. Macrolide antibiotics modulate ERK phosphorylation and IL-8 and GM-CSF production by human bronchial epithelial cells. Am J Physiol Lung Cell Mol Physiol. 2006;290:L75–85.CrossRefPubMed
17.
Wacker K, Denker S, Hildebrand A, Eberwein P, Reinhard T, Schwartzkopff J. Short-term azithromycin treatment promotes cornea allograft survival in the rat. PLoS One. 2013;8:e82687.CrossRefPubMedPubMedCentral
18.
Medina CA, Rowe AM, Yun H, Knickelbein JE, Lathrop KL, Hendricks RL. Azithromycin (AZM) treatment increases survival of high-risk corneal allotransplants. Cornea. 2013;32:658–66.CrossRefPubMedPubMedCentral
19.
Iwamoto S, Azuma E, Kumamoto T, Hirayama M, Yoshida T, Ito M, et al. Efficacy of azithromycin in preventing lethal graft-versus-host disease. Clin Exp Immunol. 2013;171:338–45.CrossRefPubMedPubMedCentral
20.
Hertzog MA. Considerations in determining sample size for pilot studies. Res Nurs Health. 2008;31:180–91.CrossRefPubMed
21.
22.
Williams NT. Medication administration through enteral feeding tubes. Am J Health Syst Pharm. 2008;65:2347–57.CrossRefPubMed
23.
Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT. Recommendations for the use of medications with continuous enteral nutrition. Am J Health Syst Pharm. 2009;66:1458–67.CrossRefPubMed
24.
Chow LW, Yuen KY, Woo PC, Wei WI. Clarithromycin attenuates mastectomy-induced acute inflammatory response. Clin Diagn Lab Immunol. 2000;7:925–31.PubMedPubMedCentral
25.
Eremenko AA, Chernova EV, Vinnitskii LI, Buniatian KA, Inviiaeva EV, Bogomolova NS, et al. Effect of clarithromycin on the systemic inflammatory response syndrome severity in patients after myocardial revascularization surgery. Anesteziol Reanimatol. 2012;3:67–71.
26.
Xu ZG, Gao Y, He JG, Xu WF, Jiang M, Jin HS. Effects of azithromycin on Pseudomonas aeruginosa isolates from catheter-associated urinary tract infection. Exp Ther Med. 2015;9:569–72.CrossRefPubMed
27.
Saini H, Chhibber S, Harjai K. Azithromycin and ciprofloxacin: a possible synergistic combination against Pseudomonas aeruginosa biofilm-associated urinary tract infections. Int J Antimicrob Agents. 2015;45:359–67.CrossRefPubMed
28.
Metadata
Title
Effects of pre-transplant azithromycin administration on kidney graft function: study protocol for a double-blind randomized clinical trial
Authors
Gholamreza Mokhtari
Mojtaba Teimoori
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Trials / Issue 1/2018
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/s13063-018-2744-y

Other articles of this Issue 1/2018

Trials 1/2018 Go to the issue

Study protocol

Palliative long-term abdominal drains versus repeated drainage in individuals with untreatable ascites due to advanced cirrhosis: study protocol for a feasibility randomised controlled trial

Research

The Comparative Effectiveness of Innovative Treatments for Cancer (CEIT-Cancer) project: Rationale and design of the database and the collection of evidence available at approval of novel drugs

Study protocol

Safe Birth and Cultural Safety in southern Mexico: study protocol for a randomised controlled trial

Research

Exposure to a multi-level multi-component childhood obesity prevention community-randomized controlled trial: patterns, determinants, and implications

Study protocol

PATCH: posture and mobility training for care staff versus usual care in care homes: study protocol for a randomised controlled trial

Research

Challenges recruiting to a proof-of-concept pharmaceutical trial for a rare disease: the trigeminal neuralgia experience